This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

The Clinical Trials Industry’s Weekly Update: News, Analysis and Insider Insights Delivered Straight To Your Inbox

Europe approves Goldman and EQT’s Parexel takeover

Share this article

The European Commission has approved Goldman Sachs and EQT’s acquisition of Parexel from Pamplona capital management.

According to a statement issued on 4 November 2021, the European Commission (EC) announced it has decided, under Article 6(1) of the EU Merger Regulation, to clear the acquisition of Parexel by Goldman Sachs and EQT.

The Commission said that following a review, it “concluded that the proposed acquisition would raise no competition concerns given the very limited overlaps between the activities of the companies.”

EQT’s healthcare portfolio includes delivery tech firm Fertin Pharma, chemicals and drug manufacturer Kara Pharma and Sweden-based CDMO Recipharm, which it acquired in February.

Goldman’s current healthcare interests include 4G Clinical, a firm that provides cloud-based randomization and clinical trial services, in which it invested $230 at the end of June.

The EC decision comes just weeks after the deal was approved by competition regulators in India.

According to a statement on September 25 the Competition Commission of India (CCI) approved the acquisition of Parexel International Corporation by Phoenix Parentco after a review.

The Commission said Phoenix Parentco, the special purpose investment vehicle jointly run by EQT and Goldman Sachs, would be allowed to buy the US CRO.

Background

Plans for the acquisition emerged in July when Goldman and EQT shared details of an $8.5 billion takeover bid.

At the time Eric Liu, global co-head of Healthcare at EQT, cited Parexel’s “development and trajectory” over the past few years as the driver for the investment.

Similarly Jo Natauri, Goldman’s head of private healthcare investing, said the CRO’s “distinguished track record of delivering clinical excellence to their large pharma and biotech customers” was key.

Parexel’s $8.5 billion price tag represents a big return on investment for Pamplona, which originally paid $5 billion for the CRO in 2017.

Image: Stock Photo Secrets

Share this article

Sign up for Clinical Insider email updates